Alexandria Venture Investments, LLC is a venture capital firm established in 1996 and located in Pasadena, California. As a subsidiary of Alexandria Real Estate Equities, the firm specializes in seed, early-stage, and growth capital investments primarily within the healthcare sector. Its focus areas include biopharma, diagnostics, life sciences, research tools, agrifood technology, and technology. By leveraging its extensive industry expertise and a robust network of relationships with leading investors and scientific advisors, Alexandria Venture Investments aims to support innovative companies that are developing breakthrough technologies and therapies to enhance human health.
The National Institutes of Health (NIH) is a leading biomedical research facility in the United States, operating under the Department of Health and Human Services. Established in 1887 and based in Bethesda, Maryland, NIH is the primary agency responsible for biomedical and health-related research in the country. It comprises 27 separate institutes and centers, each focusing on different disciplines within biomedical science. NIH conducts its own scientific research through the Intramural Research Program and provides significant funding for research at external institutions via the Extramural Research Program. With a workforce that includes 1,200 principal investigators and over 4,000 postdoctoral fellows, NIH has been instrumental in major medical breakthroughs, such as the development of vaccines for hepatitis and human papillomavirus, as well as the discovery of treatments for various health conditions. As the world's largest source of medical research funding, NIH continues to advance scientific knowledge and contribute to public health improvements.
SOSV is a global venture capital firm based in Princeton, New Jersey, founded in 1995. It specializes in early-stage investments, focusing on deep technology innovations that address human and planetary health. The firm operates startup development programs, notably HAX and IndieBio, which provide resources, facilities, and lab equipment to accelerate the growth of promising startups. SOSV supports companies from their inception through various funding stages, including seed and series A rounds, while offering ongoing assistance to help them scale and attract additional investors. By concentrating on revolutionary technologies and cross-border markets, particularly in Asia, SOSV aims to foster significant advancements that benefit humanity and the environment.
OrbiMed is a healthcare-focused investment firm based in New York City, established in 1989. The firm specializes in providing a range of financing solutions, including bridge loans, senior debt, and structured debt capital for both commercial-stage public and private healthcare companies. OrbiMed invests across various sectors within the healthcare industry, such as pharmaceuticals, life sciences, digital health, medical devices, biopharmaceuticals, diagnostics, healthcare technology, and biotechnology. With approximately $5 billion in assets under management, OrbiMed aims to support a spectrum of healthcare companies, from early-stage ventures to established multinational corporations.
ARCH Venture Partners, founded in 1986 and based in Chicago, Illinois, is a venture capital firm that specializes in investing in early-stage technology companies, particularly in the life sciences sector. The firm focuses on innovations that emerge from academic research institutions and national laboratories, making it a recognized leader in the commercialization of such technologies. ARCH invests conservatively in seed rounds to mitigate risk and subsequently leads or co-leads further financing rounds, aiming for a seat on the Board of Directors. Its investment strategy encompasses a wide range of sectors, including biotechnology, pharmaceuticals, advanced materials, and clean technology, among others. ARCH primarily invests in the United States while also targeting opportunities in countries like Canada, Ireland, South Korea, China, and Japan. The firm has raised over $3 billion across ten venture funds and has supported more than 150 companies in their early capital rounds.
Sofinnova Partners is a venture capital firm founded in 1972 and headquartered in Paris, France. The firm specializes in investing in the life sciences sector, focusing on biopharmaceuticals, biotechnology, medical devices, and industrial biotechnology. With over €2 billion in assets dedicated to life science investments, Sofinnova Partners partners with entrepreneurs at various stages, from seed to later-stage companies, including start-ups and corporate spin-offs. The firm actively seeks to take a lead role in financing, often becoming the first institutional investor in Series A rounds. It maintains an engaged presence in its portfolio companies by sitting on their boards and supporting them through to exit, thereby fostering transformative innovations that have the potential to make a significant positive impact on society.
RA Capital Management is a Boston-based investment advisor founded in 2004, specializing in the life sciences and healthcare sectors. The firm focuses on early-stage companies developing innovative technologies, products, and services in drug development, medical devices, diagnostics, and research tools. With a team of professionals trained in biology, chemistry, and medicine, RA Capital Management leverages its extensive industry and business development experience to identify and invest in promising healthcare ventures. As a Registered Investment Adviser, the firm employs a strategic approach that includes both venture capital investments and a hedge fund strategy, targeting opportunities primarily in the United States and Europe.
Perceptive Advisors LLC is an investment management firm established in 1999, with headquarters in New York City and an additional office in Boston. The firm specializes in supporting the life sciences sector, investing primarily in biotechnology, pharmaceuticals, medical devices, diagnostics, and healthcare services. Perceptive Advisors engages in venture capital and incubation, making equity investments ranging from $10 million to $200 million in both private and public companies. It manages client-focused equity portfolios and employs a long/short equity strategy as part of its hedging techniques. Additionally, the firm conducts in-house research and utilizes technical analysis to inform its investment decisions. Perceptive Advisors also provides customized debt financing solutions through its Perceptive Credit Opportunities Fund, catering to the evolving needs of healthcare companies.
IndieBio, founded in 2014 and based in San Francisco, is the world’s first accelerator dedicated to startups that leverage biology to address significant global challenges. As part of SOSV, a global venture capital firm, IndieBio focuses on nurturing seed-stage and early-stage companies across various sectors, including healthcare, life sciences, biotechnology, and consumer products. The accelerator provides funding and support to innovative ventures aiming to create impactful solutions in areas such as pharmaceuticals, oncology, and advanced manufacturing. By fostering emerging technologies and biological applications, IndieBio plays a crucial role in advancing the next generation of startups that seek to make a positive difference in society.
GV Investment Managers is a private equity firm founded in 2000 and based in Stamford, Connecticut. The firm specializes in impact investing, private equity, and portfolio management services. It focuses on sectors such as life sciences, consumer products, enterprise solutions, cryptocurrency, climate technology, and frontier innovations. With Alphabet as its sole limited partner, GV Investment Managers primarily targets investments in North America and Europe. The firm collaborates with operating partners who assist startups in areas such as design, diversity and inclusion, talent acquisition, and engineering, while also facilitating connections with Google for technological support and expertise.
Khosla Ventures, founded in 2004 and headquartered in Menlo Park, California, is a venture capital firm that provides strategic advice, capital, and support to bold entrepreneurs across various sectors. The firm focuses on early-stage investments in areas such as artificial intelligence, climate technology, sustainability, enterprise solutions, consumer products, fintech, digital health, medical technology, and therapeutics. Khosla Ventures is particularly interested in innovative solutions that address significant socio-economic challenges and enhance productivity, especially for low-income populations and small businesses in emerging markets. The firm embraces experimentation and is open to investing in unconventional and high-risk ventures, often acting as the sole investor in groundbreaking projects. With a commitment to fostering impactful entrepreneurship, Khosla Ventures seeks to create value through technological advancements and creative business models, with a special emphasis on markets in South Asia.
Eli Lilly and Company is a global pharmaceutical firm engaged in the discovery, development, manufacture, and sale of a wide range of medical products. The company operates facilities in the United States, Puerto Rico, and 25 other countries, distributing its products in approximately 135 countries worldwide. Eli Lilly specializes in various therapeutic areas, including neuroscience, cardiometabolic diseases, cancer, and immunology. Its key offerings include Verzenio for cancer treatment, Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic conditions, as well as Taltz and Olumiant for immunological disorders. In addition to human health, the company conducts research aimed at treating diseases in animals and enhancing the efficiency of animal food production.
Novo Holdings is a Danish holding and investment firm based in Copenhagen, wholly owned by the Novo Nordisk Foundation. Established in 1999, it manages the Foundation's financial assets and aims to ensure sufficient dividends to support its grant obligations for medical and scientific research. Novo Holdings primarily invests in the life science sector, maintaining a diverse portfolio that includes equities, bonds, real estate, infrastructure, and private investments. It holds a significant ownership stake in Novo Nordisk A/S and Novozymes A/S, ensuring a material influence over these companies. The firm actively participates in their governance and is committed to supporting early-stage applied research in life sciences through initiatives like Novo Seeds. By investing in both early and later-stage life science companies, Novo Holdings seeks to balance financial risk while aiming for high returns, all within a framework of shared values and management principles across the Novo Group.
The National Science Foundation (NSF) is an independent federal agency established in 1950 and based in Alexandria, Virginia. It is dedicated to supporting research and education in science and engineering across a wide range of disciplines. The NSF provides significant non-dilutive funding, up to $1.5 million, to startups and small businesses through its America's Seed Fund initiative, which is part of the Small Business Innovation Research (SBIR) program mandated by Congress. With an operating budget of approximately $7.8 billion, the NSF is committed to advancing fundamental research and education, thus fostering innovation and technological development in the United States.
Casdin Capital is a New York-based investment firm established in 2012, specializing in fundamental research within the life sciences and healthcare sectors. The firm focuses on a range of investments, from early-stage to late-stage private opportunities, and is particularly interested in areas such as oncology, digital health, and agtech. As a Registered Investment Adviser, Casdin Capital employs a long-short equity strategy to manage its portfolio. Founded by Eli Casdin, the firm has built a reputation for its analytical approach to investing in innovative healthcare solutions, aiming to capitalize on advancements in the industry. As of October 2020, Casdin Capital managed approximately $2.2 billion in assets.
Polaris Partners is a multibillion-dollar investment firm founded in 1996 and headquartered in Boston, Massachusetts, with an additional office in San Francisco. The firm specializes in investing in healthcare and biotechnology companies, focusing on various aspects of the sector. Its healthcare portfolio includes companies that develop innovative care delivery models, such as digital health solutions, consumer-centric services, patient-provider interactions, as well as data science and analytics. In the biotechnology realm, Polaris targets life sciences firms engaged in research and development of therapeutics, genomic technologies, and molecular platforms. With over 20 years of experience, Polaris Partners collaborates with repeat entrepreneurs and innovators, supporting ventures from their inception through to profitable growth.
Lux Capital is a venture capital firm established in 2000 and headquartered in New York, New York. The firm specializes in investments in early-stage and growth companies, focusing on sectors such as biochemistry, material science, electronics, infrastructure, and aerospace. With over $5 billion in assets under management, Lux Capital takes an active role in supporting entrepreneurs, aiming to build successful businesses in high-growth industries. The investment team has a track record of founding more than 20 companies, employing strategies that enhance connectivity, insight, and competitive leadership for its portfolio companies. As a Registered Investment Adviser, Lux Capital is committed to fostering innovation at the intersection of technology and the sciences.
Janus Henderson Investors is a global asset management firm headquartered in London, United Kingdom, with a history dating back to 1934. The company specializes in delivering investment performance and services to a diverse clientele, including institutional, retail, and high-net-worth clients. It connects these clients with investment professionals who have expertise across a wide range of asset classes, such as equities, fixed income, real estate, and alternative investments. Janus Henderson Investors aims to provide tailored investment solutions that meet the unique needs of its clients while fostering long-term financial growth.
EcoR1 Capital, LLC is an employee-owned investment advisory firm based in San Francisco, California, founded in 2012. Specializing in the biotechnology sector, EcoR1 Capital focuses on identifying and evaluating innovative therapeutic solutions that can significantly enhance patient outcomes. The firm employs a long/short investment strategy primarily within the public equity markets of the United States, while also managing separate client-focused equity and fixed income portfolios. By investing in biotech companies that offer promising new treatments for untreated diseases, EcoR1 Capital aims to advance medical research and build upon the innovative contributions of its predecessors in the healthcare and life sciences fields.
Foresite Capital is a healthcare and life sciences investment firm founded in 2011 and based in Larkspur, California, with additional offices in San Francisco and New York. The firm adopts a data-driven and scientific approach to identify and invest in startups that leverage biology and big data to enhance healthcare outcomes. Foresite Capital focuses on multiple stages of investment in sectors such as healthcare technology, therapeutics, and life sciences. The firm collaborates closely with its portfolio companies, offering not only capital but also access to a multidisciplinary team of experts, including scientists, engineers, analysts, and clinicians. This collaborative approach aims to address significant unmet clinical needs by supporting innovative healthcare solutions across various stages of development. Foresite Capital manages $2 billion in assets and emphasizes investments in companies utilizing data science and machine intelligence to advance healthcare.
Adage Capital Management is a Boston-based $8.9B Money Management firm focused on managing S&P 500 assets predominantly for Endowments and Foundations such as Harvard University, Northwestern University, Dartmouth College, the American Red Cross and the Getty Foundation. Adage and its predecessor, the Select Equity Group at the Harvard Management Company, has outperformed the S&P index in each of the last 15 years by an average of 3.5%. The fund is run by Phill Gross, who prior to founding Adage, was a Healthcare and Retail analyst, equity research director and partner at the Harvard Management Company for 18 years..
T. Rowe Price Group is an investment management and financing advisory firm based in Baltimore, Maryland, founded in 1937. The company offers a comprehensive range of investment strategies, including debt, equities, and private equity, catering to a diverse clientele that includes individuals, high-net-worth individuals, financial institutions, retirement plan sponsors, charitable organizations, corporations, and government entities. T. Rowe Price provides services such as separate account management, mutual funds, and sub-advisory services, positioning itself as a trusted partner in managing and growing investments across various sectors. The firm is also involved in funding technology startups, reflecting its commitment to innovation and adapting to emerging market trends.
Northpond Ventures is a science-driven venture capital firm headquartered in Bethesda, Maryland. Our mission is to build a better tomorrow. Our investments are focused on life sciences, technology, and affiliated industries.
Invus Financial Advisors, LLC is an employee-owned investment firm based in New York, founded in 2006. The firm specializes in private equity investments and manages pooled investment vehicles, including hedge funds and funds of funds. Invus focuses on making direct and indirect investments in special situations, venture capital, and growth equity stages, with an emphasis on smaller companies and opportunistic co-investments. The firm adopts a flexible approach, recognizing the uniqueness of each company and the complexities of business transformation. Invus maintains a long-term commitment to its investments, aligning its incentives with those of its partners. With a history of empowering owner-managers since 1985 and a strong backing from a group of European families, Invus Financial Advisors manages over $4 billion in an evergreen fund and operates additional offices in London, Paris, and Hong Kong.
Innovate U.K. is a NPO that offers funding services to support science and technology innovations. The organization offers services and information on births, deaths, marriages, business, self-employed, childcare, parenting, citizenship, law, disabled persons, transportation, education, environment, housing, money, tax, travel, immigration, and jobs. Innovate U.K. is based in Swindon.
F-Prime Capital is a venture capital firm established in 1969 and headquartered in Cambridge, Massachusetts, with additional offices in San Francisco and London. It is part of the Fidelity Investments family, which has a long history of supporting entrepreneurs. F-Prime Capital focuses its investments on companies in North America and Europe, specializing in sectors such as healthcare, life sciences, therapeutics, fashion, medtech, health information technology and services, and technology. The firm emphasizes a hands-on approach, leveraging its deep industry expertise and extensive relationships to assist entrepreneurs in building significant companies. F-Prime Capital operates without the pressures of external fundraising, allowing it to concentrate on identifying and nurturing promising ventures.
The Bill & Melinda Gates Foundation is an independent non-profit organization based in Seattle, Washington, established in 2000. It is dedicated to reducing global inequities by focusing on improving health, alleviating extreme poverty, and supporting educational initiatives. The foundation also engages in community giving within the Pacific Northwest, promoting strategies and programs that assist low-income families. With regional offices in Washington, D.C.; New Delhi, India; Beijing, China; and London, United Kingdom, the foundation is governed by its co-founders, Bill and Melinda Gates, along with trustee Warren Buffett. Its mission encompasses a wide range of global challenges, aiming to create lasting change through targeted grant-making and programmatic efforts.
Versant Ventures is a healthcare investment firm founded in 1999 and based in San Francisco, California. It focuses on supporting exceptional entrepreneurs in building innovative companies across various sectors within healthcare, including biotechnology, life sciences, pharmaceuticals, and oncology. With $2.3 billion under management, the firm invests at all stages of company development, emphasizing the discovery and development of novel therapeutics. Versant’s team possesses extensive investment, operational, and scientific expertise, allowing for a hands-on approach to company building. Since its inception, more than 65 companies associated with Versant have successfully achieved acquisitions or initial public offerings, reflecting the firm’s commitment to fostering growth in the healthcare industry.
DCVC is a venture capital firm founded in 2010 and based in Palo Alto, California. It specializes in investing in deep technology sectors that leverage advancements in artificial intelligence, exascale computing, climate science, robotics, and life sciences, among others. The firm supports entrepreneurs who aim to address significant challenges by harnessing cutting-edge scientific and technological innovations. By focusing on transformative companies that optimize costs and enhance productivity, DCVC seeks to create solutions that benefit wider society while pushing the boundaries of technological capability. The firm is particularly interested in early-stage ventures in synthetic biology, medicine, and agriculture, reflecting its commitment to fostering deep technological change across various industries.
Flagship Pioneering conceives, creates, resources, and grows first-in-category ventures to transform human health and sustainability. The company accelerates Flagship Pioneering’s advances in biology, engineering, medicine, energy, and beyond. The firm harnesses science and entrepreneurialism to envision alternative futures, beginning with seemingly unreasonable propositions and navigating to transformational outcomes through an evolutionary methodology. Flagship Pioneering combines innovative capacity, entrepreneurial leadership, and professional capital management in a single enterprise that systematically produces first-in-category companies.
HSG, formerly known as Sequoia Capital China, is a prominent venture capital and private equity firm with a global focus on technology, healthcare, and consumer sectors. Established in 2005, HSG operates offices in key international cities including Hong Kong, Shanghai, Beijing, Shenzhen, London, Tokyo, and Singapore, managing over $55 billion in assets for leading institutional investors. The firm has supported over 1,500 companies, fostering innovation and entrepreneurship through investments in transformative technologies and high-growth business models. HSG has a track record of success, with more than 160 portfolio companies having gone public and over 140 achieving unicorn status. It has developed a comprehensive investment platform that encompasses seed, venture, growth, buyout, and infrastructure investing, as well as public equities. HSG is dedicated to empowering entrepreneurs and companies to create enduring enterprises while delivering strong returns to its limited partners. Through its extensive resources and industry expertise, HSG provides significant advantages to the companies it partners with.
Fidelity is a privately owned investment management firm that caters to a diverse clientele, including individual investors, businesses, financial advisors, and institutions. The company offers a broad range of financial services, such as retirement planning, estate planning, wealth management, and life insurance. Additionally, Fidelity specializes in discount brokerage and provides various investment products including mutual funds, annuities, and managed portfolios. The firm emphasizes the financial well-being of its clients by conducting in-house research to inform its investment strategies. With a focus on helping clients achieve their financial goals, Fidelity plays a significant role in the financial services industry.
Deerfield Management is a New York-based healthcare company founded in 1994 that operates across investment, information, and philanthropy. As a registered investment adviser, it focuses on providing a robust healthcare ecosystem through various investment strategies. The firm engages in both private and public investments, targeting companies within the life sciences, medical device, diagnostic, digital health, and health services sectors. Deerfield's commitment extends beyond financial support, as it also emphasizes the importance of information and philanthropy in enhancing healthcare outcomes.
Founded in 2009 by Marc Andreessen and Ben Horowitz, Andreessen Horowitz is a venture capital firm based in Menlo Park, California. The firm specializes in incubating and investing in startups across various stages, from seed to late-stage funding. It primarily focuses on sectors such as technology, including software, cloud computing, enterprise software, and consumer Internet. Additionally, it invests in emerging fields like artificial intelligence, fintech, and healthcare, specifically targeting companies at the intersection of technology and life sciences, such as digital therapeutics and computational medicine. Andreessen Horowitz is committed to fostering innovation and supporting companies that contribute to American dynamism, while strategically avoiding investments in areas like clean energy, transportation, and consumer retail.
Leaps by Bayer is the corporate venture capital arm of Bayer, established in 2015 and headquartered in Leverkusen, Germany. The company focuses on investing in groundbreaking advancements within the life sciences, particularly in biotechnology and agriculture. By targeting disruptive biotechnologies, Leaps by Bayer aims to make significant and lasting contributions that can profoundly impact humanity. Through its strategic investments, the firm seeks to support innovations that address critical challenges in healthcare and food production.
Atlas Venture is an early-stage venture capital firm based in Cambridge, Massachusetts, founded in 1980. The firm specializes in creating and investing in biotech startup companies, primarily in the life sciences sector, and emphasizes a seed-led venture creation strategy. Atlas Venture focuses on identifying and nurturing promising entrepreneurs to build scalable businesses that can deliver significant value. The firm has a history of successful investments, with a portfolio that includes over 350 companies across various countries, resulting in numerous acquisitions and public offerings. Atlas Venture typically invests between $500,000 and $5 million in its early-stage ventures, and its investment team consists of experienced operating executives and venture capitalists. The firm has established separate teams dedicated to life sciences and technology, with the life sciences group retaining the Atlas name.
New Enterprise Associates, Inc. is a private equity and venture capital firm founded in 1977 and headquartered in Menlo Park, California, with additional offices in India and China. The firm specializes in investing across various stages of business development, from seed funding to public offerings, with a strong emphasis on the technology and healthcare sectors. Its investment strategy encompasses a wide range of industries, including information technology, consumer internet, financial technology, software, healthcare services, life sciences, biopharmaceuticals, and energy technology. New Enterprise Associates actively engages with entrepreneurs to support the growth of their companies, making investments between $0.05 million and $20 million. The firm has a global investment focus, particularly in regions such as Asia, Brazil, and the United States.
RTW Investments, LP is an employee-owned hedge fund manager based in New York, with additional offices in London and Shanghai. Established in 2009, the firm specializes in investments within the healthcare sector, focusing on life sciences, big data, and digital health. RTW Investments engages in a comprehensive investment strategy that spans the entire lifecycle of healthcare companies, including company creation, early-stage venture capital, alternative financing, and public company investments. The firm conducts thorough in-house fundamental research to inform its investment decisions, managing both pooled investment vehicles and separate client-focused equity and fixed income portfolios.
Section 32 is a venture capital firm founded by Bill Maris, who previously established Google Ventures. The firm is based in San Diego and focuses on investing in groundbreaking technologies that aim to enhance the human condition. Section 32's investment strategy encompasses a wide range of sectors, including artificial intelligence, enterprise software, cybersecurity, fintech, quantum computing, computational biology, and biotechnology. With a team experienced in building successful companies, Section 32 seeks to accelerate the discovery, development, and distribution of revolutionary innovations.
Surveyor Capital is a fundamental equities business. Surveyor’s sector-aligned investment teams aim to generate alpha through a deep understanding of each company’s strategy, management teams, drivers of performance, and cyclical and secular industry trends over the medium and long term.
Qiming Venture Partners is a prominent venture capital firm based in Shanghai, China, founded in 2006. With additional offices in Beijing, Suzhou, Hong Kong, and Singapore, the firm focuses on early to growth-stage investments across various sectors, including healthcare, information technology, consumer goods, mobile internet, artificial intelligence, and clean technology. Qiming Venture Partners has a strong track record, having invested in over 530 innovative companies, with more than 200 achieving successful exits through public offerings or mergers and acquisitions. The firm is recognized for its deep technical expertise and hands-on operational support, making it a preferred partner for CEOs and startups seeking to scale their operations. Its partners are often sought after as board members, reflecting their status as respected business leaders and thought leaders in the venture capital landscape.
Future Planet Capital is a London-based venture capital firm established in 2015 that focuses on investing in growth companies emerging from leading universities and research institutions worldwide. The firm targets sectors including climate change, education, health, security, and sustainable growth, emphasizing the commercialization of innovative technologies that address pressing global challenges. With a portfolio that comprises over 300 companies and includes 60 successful exits, Future Planet Capital is dedicated to supporting breakthrough advancements that contribute to a sustainable future. The firm manages substantial capital on behalf of institutional investors, reflecting its commitment to impact-driven investments.
SoftBank Investment Advisers is a venture capital firm established in 2017 and headquartered in London, United Kingdom. It operates as a subsidiary of SoftBank Group Corp. and specializes in growth capital and late-stage investments predominantly within the technology sector. The firm focuses on a diverse array of industries, including internet-of-things, artificial intelligence, robotics, telecommunications, computational biology, fintech, and digital financial services. With a preference for global investments, particularly in the United States, SoftBank Investment Advisers typically commits a minimum of $100 million to both minority and majority stakes in private and public companies. The firm is known for offering operational expertise and leveraging a vast global network, aiming to support innovative companies that have the potential to revolutionize their respective fields. It maintains additional offices in key locations such as Tokyo, San Francisco, and Singapore.
Farallon Capital Management, L.L.C. is a privately owned asset management firm based in San Francisco, California, founded in March 1986 by Thomas F. Steyer. The firm specializes in managing equity capital for a diverse range of clients, including institutions such as college endowments, charitable foundations, pension plans, and high-net-worth individuals. Farallon invests globally across developed and emerging markets, focusing on public and private debt and equity securities, as well as direct investments in private companies and real estate. Its investment strategies encompass credit investments, long/short equity, merger arbitrage, and real estate-related investments. The firm employs a value-driven approach, utilizing fundamental analysis and a bottom-up stock-picking methodology, supported by both in-house and external research. Farallon has expanded its presence with additional offices in Europe, Asia, and South America, and is known for its significant investment activities in various global markets.
Digitalis Ventures is a venture capital firm established in 2016 and headquartered in New York, New York, with additional offices in Boston, Los Angeles, and San Francisco. The firm focuses on investing in solutions addressing complex challenges in human and animal health, engaging with entrepreneurs, inventors, and scientists across various stages of venture investing. Digitalis Ventures emphasizes a comprehensive approach to healthcare, making investments that span the entire healthcare ecosystem, including sectors such as healthcare, life sciences, and animal health. As a Registered Investment Adviser, Digitalis Ventures is committed to fostering innovation in these critical areas.
Lilly Asia Ventures, established in 2008 and based in Shanghai, China, serves as the corporate venture capital arm of Eli Lilly and Company. The firm focuses on making investments in promising life science companies that exhibit strong management teams and innovative technologies or business models. While its primary investment strategy targets opportunities in China, Lilly Asia Ventures is also open to exploring prospects in other regions of East and South Asia. The firm invests across various stages, including seed, early, and later stages, with particular interest in sectors such as healthcare, life sciences, oncology, manufacturing, and technology-based industries. Through its investments, Lilly Asia Ventures aims to foster the development of innovative solutions that contribute to improved health and quality of life.
Wellington Management Company, founded in 1928 and headquartered in Boston, Massachusetts, is an investment management firm that caters to a diverse range of institutional clients, including high-net-worth individuals, pension plans, endowments, insurers, and government entities. The firm employs a comprehensive approach to investment management that encompasses equity, fixed income, currency, commodity, and alternative markets. Wellington Management offers various services, including asset allocation, multi-manager strategies, and specialized investment approaches. The firm is known for its focus on both growth and value stocks across small-cap, mid-cap, and large-cap companies, and it manages a variety of investment vehicles, such as mutual funds and hedge funds, to meet the unique needs of its clientele.
Suvretta Capital Management is an investment management company. The firm manages three strategies: a generalist long/short equity strategy and two healthcare-focused long/short strategies.
Forbion Capital Partners is a Netherlands-based venture capital firm focused on investing in life sciences companies in drug development as well as MedTech companies addressing high medical needs. Forbion's investment team of nine investment professionals has built an impressive performance track record since the late nineties with successful investments in Rhein Biotech, Crucell, Neutec, Glycart, Borean, Impella, Alantos, Acorda, Fovea and PanGenetics. Current assets under management exceed €400m ($500m), split between three active funds. Finally, Forbion co-manages BioGeneration Ventures, an early stage fund focused on academic spin-outs and seed investments in the Netherlands.